Today: 9 June 2026
Marvell moves as earnings nears, eyes on AI chips

Marvell moves as earnings nears, eyes on AI chips

New York, May 20, 2026, 05:07 (EDT)

Marvell Technology stock edged up early Wednesday, after a jump on Tuesday as traders returned to AI-infrastructure chip names. The company reports fiscal Q1 earnings next week.

Marvell (MRVL) closed Tuesday up 4.35% at $176.27 after hitting $181.64 earlier in the session. Ahead of the open, Google Finance showed Marvell trading at $184.25, up 4.53% in premarket action.

Market attention is on the calendar. Marvell will report fiscal first-quarter 2027 numbers after the close on May 27, with a call set for 1:45 p.m. Pacific. Investors get a week to see if demand for custom AI chips and networking hardware still exceeds what’s available.

Nasdaq opens trading at 9:30 a.m. EDT, while premarket kicks off at 4 a.m. and goes until the bell. Volumes are usually lighter and swings can be bigger before the open. Wednesday is a standard session. The next market holiday is Memorial Day on May 25.

Wall Street is focused on inference, which means using AI models once training is done, and also on ASICs, or chips built for a single task. Evercore ISI lifted its Marvell target to $155 from $133 and kept an Outperform, saying its checks turned up more big cloud buyers interested in their own ASICs and accelerators.

Marvell’s price target got a boost at Melius Research, with analyst Ben Reitzes raising it to $220 from $140 and keeping a Buy rating. Reitzes said his team is “incrementally good” on memory and AI chip names at the moment. He called Marvell one of the “bottleneck stocks,” or companies tied to AI where shortages could pop up. TipRanks

CLSA upgraded Marvell and Advanced Micro Devices to Outperform and boosted Marvell’s price target to $225 from $90, AASTOCKS Financial News reported. Broadcom’s Outperform rating was unchanged. The update puts Marvell next to Nvidia, Broadcom, and AMD as names in the AI hardware space, even as the group competes and works together across compute, networking and custom silicon.

Asian shares slipped and Nasdaq futures fell slightly on Wednesday as chips stayed volatile, Reuters reported, with higher bond yields pressuring tech. Nvidia reports earnings soon. “It’s a corrective pullback” after an “absolutely phenomenal rally,” Tony Sycamore at IG said. Reuters

PHLX Semiconductor Index fell 3% Monday, adding to a 4% slide Friday. The index is still up about 59% for the year, Schwab said. Liz Ann Sonders of Schwab Center for Financial Research said the market’s narrow move and fast changes under the surface may keep going for a while.

Marvell shares now trade with AI spending in mind. In March, the company reported record fiscal 2026 revenue of $8.195 billion. CEO Matt Murphy pointed to “robust AI demand” and said bookings are climbing at a “record pace.” SEC

Nvidia and Marvell’s March 31 deal involves NVLink Fusion, silicon photonics, and scale-up networking, with Nvidia investing $2 billion in Marvell. Nvidia CEO Jensen Huang called it an “inference inflection.” Marvell CEO Murphy cited “high-speed connectivity” and “optical interconnect” as the way to scale AI. Marvell Technology, Inc.

But the risks are obvious. Options market data shows implied volatility is running in the top 10% for the year, with traders pricing about a 50% shot Marvell swings more than 13.23%, or $22.51, on its results. With the stock up, there isn’t much safety if Nvidia misses on AI spending or Marvell’s guide disappoints.

Marvell isn’t trading on AI right now. This trade is more about whether the company’s numbers next week can match a stock that’s been moving like a scarce data-center supplier.

Stock Market Today

  • United Natural Foods Q3 Earnings Miss Estimates Despite Growth
    June 9, 2026, 10:13 AM EDT. United Natural Foods (UNFI) reported Q3 earnings of $0.77 per share, missing the Zacks Consensus Estimate of $0.81, marking a -5.34% earnings surprise. Revenues fell 2.02% short at $7.72 billion versus the expected $7.89 billion, down from $8.06 billion last year. The specialty foods distributor has beaten earnings estimates three times in the past four quarters but topped revenue estimates only once. UNFI shares have gained 53.4% year-to-date, far outpacing the S&P 500's 8.2% rise. The stock holds a Zacks Rank #3 (Hold), signaling expected in-line performance with the market amid mixed earnings estimate revisions. Industry outlook remains cautious with Food - Miscellaneous ranking in the bottom 16% according to Zacks.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
SpaceX restarts Starlink launches after satellite mishap — and another Falcon 9 is already queued
Previous Story

Goldman Said to Get Lead Spot as SpaceX IPO Nears $1.75 Trillion Listing

Bolt CEO Points to HR Firings as Solution, Details Aftermath
Next Story

Bolt CEO Points to HR Firings as Solution, Details Aftermath

Go toTop